| Peter Kyle |
2025-04-01 |
Oracle |
To discuss Oracle Whitepaper on digital transformation of the NHS |
|
|
|
|
|
| Peter Kyle |
2025-04-02 |
Gilead Sciences |
To discuss Gilead's role in HIV prevention and issues facing the life sciences sector in the UK |
|
|
|
|
|
| Peter Kyle |
2025-04-02 |
Merck |
To discuss challenges and opportunities facing the UK life sciences sector, including medicines pricing, clincal trials and AI |
|
|
|
|
|
| Peter Kyle |
2025-04-02 |
Astrazeneca, Chiesi, Moderna, Menarini, Bristol-Mysers Squibb, Pfizer, Amgen, MSD, Johnson & Johnson, TEVA, Almirall, Merck, Incyte, Sanofi, Servier, IPSEN, Novartis, Gilead, Bayer, Chugai, Eli Lilly, Roche, USB, Mitsubishi, Lundbeck, Biogen, Takeda, Boehringer Ingelheim, GSK, Association of the British Pharmaceutical Idustry, JPMA, European Federation of Pharmaceutical Infustries and Association, Government Affairs Gilead Sciences, INTERPAT, International Federation of Pharmaceutical Manufacturers and Associations, Global Policy Roche, Pharmaceutical Research and Manufacturers of America, MHRA, John Symons, John Bell, Jason Chin, Wellcome Trust, University of Cambridge, University of Manchester, University of Oxford, Francis Crick Institute |
Roundtable discuss issues facing life sciences in the UK, including VPAG, clincial trials, and health data |
|
|
|
|
|
